{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:27:43Z","timestamp":1793734063374,"version":"4.6.1"},"reference-count":115,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acquired resistance to targeted, nonintensive therapies is common in myeloid malignancies. However, the kinetics of selection, the hematopoietic cell compartments in which selection occurs, and the molecular mechanisms underlying selection remain open questions. To address this, we studied the kinetics of clonal and transcriptional responses to combinational therapy with ivosidenib plus venetoclax, with or without azacitidine, across hematopoiesis in 8 patients with IDH1-mutant myeloid malignancy. All 8 patients initially responded to treatment, but 6 relapsed, whereas 2 remained in sustained remission for &amp;gt;4 years. We performed combined high-sensitivity single-cell genotyping and scRNA sequencing in index-sorted sequential patient samples. In all patients, clonal selection occurred rapidly, within 1 to 3 treatment cycles. Clonal selection preceded treatment failure by months to years. Relapse was associated with expansion of either clones harboring newly detected myeloid driver mutations or preexisting minor clones that underwent differentiation delay upon treatment exposure. In both cases, clonal selection occurred within immature cell populations previously shown to contain leukemic stem cell potential. Different genetic alterations within relapse-associated clones converged onto common upregulated transcriptional programs of stemness, branched-chain amino acid catabolism, and genes sensitive to menin inhibition. Importantly, this relapse-associated transcriptional signature was selected within 3 cycles of therapy. In contrast, in both patients remaining in remission, leukemic clones were rapidly eradicated, and replaced by clonal and wild-type hematopoiesis. Overall, in patients treated with ivosidenib combination therapy, rapid clonal selection occurs within the first treatment cycles. In those patients destined to relapse, genetically heterogeneous resistant clones are characterized by common transcriptional programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027948","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:01:09Z","timestamp":1762365669000},"page":"613-632","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3377-1170","authenticated-orcid":false,"given":"Sven","family":"Turkalj","sequence":"first","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6491-2573","authenticated-orcid":false,"given":"Felix A.","family":"Radtke","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-9145","authenticated-orcid":false,"given":"Bilyana","family":"Stoilova","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9374-300X","authenticated-orcid":false,"given":"Rabea","family":"Mecklenbrauck","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus J.","family":"Groom","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-5085","authenticated-orcid":false,"given":"Niels Asger","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-0624","authenticated-orcid":false,"given":"Curtis A.","family":"Lachowiez","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1806-0952","authenticated-orcid":false,"given":"Marlen","family":"Metzner","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batchimeg","family":"Usukhbayar","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian Angulo","family":"Salazar","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zeng","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9595-1279","authenticated-orcid":false,"given":"Jennifer","family":"Marvin-Peek","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"K\u00f6rber","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas","family":"Issa","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Symeonidou","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-8608","authenticated-orcid":false,"given":"Anne P.","family":"de Groot","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-0914","authenticated-orcid":false,"given":"Paresh","family":"Vyas","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"4Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2026020612013801500_bib1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"2026020612013801500_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"149","key":"2026020612013801500_bib3","doi-asserted-by":"crossref","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7488","key":"2026020612013801500_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"7","key":"2026020612013801500_bib5","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026020612013801500_bib6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"2026020612013801500_bib7","doi-asserted-by":"crossref","first-page":"12475","DOI":"10.1038\/ncomms12475","article-title":"Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia","volume":"7","author":"Hirsch","year":"2016","journal-title":"Nat Commun"},{"issue":"6","key":"2026020612013801500_bib8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"7834","key":"2026020612013801500_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"8","key":"2026020612013801500_bib10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.stem.2024.05.010","article-title":"Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging","volume":"31","author":"Jakobsen","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2026020612013801500_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"issue":"8","key":"2026020612013801500_bib12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.20151775","article-title":"Genetically distinct leukemic stem cells in human CD34\u2212 acute myeloid leukemia are arrested at a hemopoietic precursor-like stage","volume":"213","author":"Quek","year":"2016","journal-title":"J Exp Med"},{"issue":"8","key":"2026020612013801500_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"2026020612013801500_bib14","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.26.573390","article-title":"Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML","author":"Zeng","year":"1  2024","journal-title":"bioRxiv"},{"issue":"3","key":"2026020612013801500_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s43018-021-00177-w","article-title":"Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia","volume":"2","author":"Hashimoto","year":"2021","journal-title":"Nat Cancer"},{"issue":"6","key":"2026020612013801500_bib16","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"2026020612013801500_bib17","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"2026020612013801500_bib18","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2026020612013801500_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026020612013801500_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2026020612013801500_bib21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026020612013801500_bib22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"16","key":"2026020612013801500_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2026020612013801500_bib24","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","article-title":"An overview of targeted therapies in acute myeloid leukemia","volume":"7","author":"Turkalj","year":"2023","journal-title":"HemaSphere"},{"issue":"11","key":"2026020612013801500_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2026020612013801500_bib26","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"issue":"8041","key":"2026020612013801500_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"6","key":"2026020612013801500_bib28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2026020612013801500_bib29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"2026020612013801500_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/leu.2009.212","article-title":"Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1\/Noxa axis","volume":"24","author":"Kojima","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2026020612013801500_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2026020612013801500_bib32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"2026020612013801500_bib33","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2026020612013801500_bib34","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"issue":"5","key":"2026020612013801500_bib35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"2026020612013801500_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"2026020612013801500_bib37","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"2026020612013801500_bib38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.stem.2025.04.012","article-title":"Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia","volume":"32","author":"Sirenko","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"4","key":"2026020612013801500_bib39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2026020612013801500_bib40","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","article-title":"Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing","volume":"73","author":"Rodriguez-Meira","year":"2019","journal-title":"Mol Cell"},{"issue":"2","key":"2026020612013801500_bib41","doi-asserted-by":"crossref","first-page":"103832","DOI":"10.1016\/j.xpro.2025.103832","article-title":"Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq","volume":"6","author":"Jakobsen","year":"2025","journal-title":"STAR Protoc"},{"issue":"10","key":"2026020612013801500_bib42","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2026020612013801500_bib43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.stem.2023.04.012","article-title":"GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells","volume":"30","author":"Turkalj","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2026020612013801500_bib44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2026020612013801500_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41592-019-0654-x","article-title":"Orchestrating single-cell analysis with Bioconductor","volume":"17","author":"Amezquita","year":"2020","journal-title":"Nat Methods"},{"issue":"6190","key":"2026020612013801500_bib46","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"issue":"11","key":"2026020612013801500_bib47","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1101\/gr.220707.117","article-title":"Single-cell sequencing data reveal widespread recurrence and loss of mutational hits in the life histories of tumors","volume":"27","author":"Kuipers","year":"2017","journal-title":"Genome Res"},{"issue":"1","key":"2026020612013801500_bib48","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13059-015-0844-5","article-title":"MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data","volume":"16","author":"Finak","year":"2015","journal-title":"Genome Biol"},{"key":"2026020612013801500_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-0716-1534-8_10","volume-title":"Modeling Transcriptional Regulation: Methods and Protocols","author":"Kumar","year":"2021","edition":"1st ed"},{"issue":"11","key":"2026020612013801500_bib50","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nmeth.4463","article-title":"SCENIC: single-cell regulatory network inference and clustering","volume":"14","author":"Aibar","year":"2017","journal-title":"Nat Methods"},{"issue":"2","key":"2026020612013801500_bib51","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2643-3230.BCD-23-0195","article-title":"IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation","volume":"5","author":"Landberg","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"2026020612013801500_bib52","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"2026020612013801500_bib53","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.1038\/s41467-023-43573-9","article-title":"Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts","volume":"14","author":"Hackert","year":"2023","journal-title":"Nat Commun"},{"issue":"43","key":"2026020612013801500_bib54","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2026020612013801500_bib55","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41592-023-02014-7","article-title":"Extending support for mouse data in the Molecular Signatures Database (MSigDB)","volume":"20","author":"Castanza","year":"2023","journal-title":"Nat Methods"},{"issue":"10","key":"2026020612013801500_bib56","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.stem.2021.07.003","article-title":"TFEB-mediated endolysosomal activity controls human hematopoietic stem cell fate","volume":"28","author":"Garc\u00eda-Prat","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2026020612013801500_bib57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2643-3230.BCD-20-0155","article-title":"Sphingosine-1-phosphate receptor 3 potentiates inflammatory programs in normal and leukemia stem cells to promote differentiation","volume":"2","author":"Xie","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026020612013801500_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.stem.2015.05.003","article-title":"Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions","volume":"17","author":"Pietras","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2026020612013801500_bib59","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41556-022-00931-x","article-title":"Hyaluronic acid\u2013GPRC5C signalling promotes dormancy in haematopoietic stem cells","volume":"24","author":"Zhang","year":"2022","journal-title":"Nat Cell Biol"},{"issue":"7633","key":"2026020612013801500_bib60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"issue":"17","key":"2026020612013801500_bib61","doi-asserted-by":"crossref","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026020612013801500_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41590-022-01370-4","article-title":"A genetic disorder reveals a hematopoietic stem cell regulatory network co-opted in leukemia","volume":"24","author":"Voit","year":"2023","journal-title":"Nat Immunol"},{"issue":"5","key":"2026020612013801500_bib63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.stem.2019.09.008","article-title":"Sphingolipid modulation activates proteostasis programs to govern human hematopoietic stem cell self-renewal","volume":"25","author":"Xie","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"9","key":"2026020612013801500_bib64","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat Genet"},{"issue":"6","key":"2026020612013801500_bib65","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molcel.2022.02.013","article-title":"MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape","volume":"82","author":"Olsen","year":"2022","journal-title":"Mol Cell"},{"issue":"6","key":"2026020612013801500_bib66","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"19","key":"2026020612013801500_bib67","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026020612013801500_bib68","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"2026020612013801500_bib69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"issue":"7954","key":"2026020612013801500_bib70","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"7778","key":"2026020612013801500_bib71","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41586-019-1652-y","article-title":"Decoding human fetal liver haematopoiesis","volume":"574","author":"Popescu","year":"2019","journal-title":"Nature"},{"issue":"4","key":"2026020612013801500_bib72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/ncb3493","article-title":"Human haematopoietic stem cell lineage commitment is a continuous process","volume":"19","author":"Velten","year":"2017","journal-title":"Nat Cell Biol"},{"key":"2026020612013801500_bib73","doi-asserted-by":"publisher","DOI":"10.1101\/060012","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"1  2021","journal-title":"bioRxiv"},{"issue":"1","key":"2026020612013801500_bib74","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI41495","article-title":"Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2R\u03b3c-deficient mice","volume":"121","author":"Sarry","year":"2011","journal-title":"J Clin Invest"},{"issue":"9","key":"2026020612013801500_bib75","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"2026020612013801500_bib76","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2026020612013801500_bib77","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2015.51","article-title":"INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia","volume":"29","author":"Dzneladze","year":"2015","journal-title":"Leukemia"},{"key":"2026020612013801500_bib78","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.25.437029","article-title":"INPP4B drives lysosome biogenesis to restrict leukemic stem cell differentiation and promote leukemogenesis","author":"Woolley","year":"11  2022","journal-title":"bioRxiv"},{"issue":"1","key":"2026020612013801500_bib79","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.1038\/s41598-019-45579-0","article-title":"SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness","volume":"9","author":"Nguyen","year":"2019","journal-title":"Sci Rep"},{"issue":"15","key":"2026020612013801500_bib80","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1101\/gad.17269211","article-title":"An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance","volume":"25","author":"Zuber","year":"2011","journal-title":"Genes Dev"},{"issue":"21","key":"2026020612013801500_bib81","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1101\/gad.1602107","article-title":"Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential","volume":"21","author":"Wong","year":"2007","journal-title":"Genes Dev"},{"issue":"4","key":"2026020612013801500_bib82","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-17-1271","article-title":"MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia","volume":"8","author":"Brown","year":"2018","journal-title":"Cancer Discov"},{"issue":"11","key":"2026020612013801500_bib83","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2007-09-113597","article-title":"HOXA9 is required for survival in human MLL-rearranged acute leukemias","volume":"113","author":"Faber","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2026020612013801500_bib84","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2012-07-442004","article-title":"PBX3 is an important cofactor of HOXA9 in leukemogenesis","volume":"121","author":"Li","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2026020612013801500_bib85","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2004-04-1583","article-title":"HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo","volume":"105","author":"Fischbach","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2026020612013801500_bib86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0092-8674(02)00697-9","article-title":"HOXB4-induced expansion of adult hematopoietic stem cells ex vivo","volume":"109","author":"Antonchuk","year":"2002","journal-title":"Cell"},{"issue":"7786","key":"2026020612013801500_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-019-1790-2","article-title":"MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment","volume":"576","author":"Calvanese","year":"2019","journal-title":"Nature"},{"issue":"18","key":"2026020612013801500_bib88","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1101\/gad.268409.115","article-title":"ERG promotes the maintenance of hematopoietic stem cells by restricting their differentiation","volume":"29","author":"Knudsen","year":"2015","journal-title":"Genes Dev"},{"issue":"6494","key":"2026020612013801500_bib89","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/371221a0","article-title":"An early haematopoietic defect in mice lacking the transcription factor GATA-2","volume":"371","author":"Tsai","year":"1994","journal-title":"Nature"},{"issue":"19","key":"2026020612013801500_bib90","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1101\/gad.1239604","article-title":"Tel\/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival","volume":"18","author":"Hock","year":"2004","journal-title":"Genes Dev"},{"issue":"21","key":"2026020612013801500_bib91","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood.V118.21.222.222","article-title":"Msi2 maintains normal hematopoietic stem cell self-renewal","volume":"118","author":"Kharas","year":"2011","journal-title":"Blood"},{"issue":"7680","key":"2026020612013801500_bib92","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature24294","article-title":"BCAT1 restricts \u03b1KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation","volume":"551","author":"Raffel","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2026020612013801500_bib93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.stem.2022.12.006","article-title":"METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism","volume":"30","author":"Han","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"24","key":"2026020612013801500_bib94","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1182\/bloodadvances.2023010460","article-title":"GPRC5C drives branched-chain amino acid metabolism in leukemogenesis","volume":"7","author":"Zhang","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026020612013801500_bib95","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.stem.2023.01.006","article-title":"Clonal hematopoiesis driven by chromosome 1q\/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia","volume":"30","author":"Sebert","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"13","key":"2026020612013801500_bib96","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026020612013801500_bib97","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2011.051532","article-title":"Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value","volume":"97","author":"Pratcorona","year":"2012","journal-title":"Haematologica"},{"issue":"13","key":"2026020612013801500_bib98","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2026020612013801500_bib99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1369\/00221554211062499","article-title":"IDH1\/2 mutations in cancer stem cells and their implications for differentiation therapy","volume":"70","author":"Molenaar","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"158","key":"2026020612013801500_bib115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"issue":"8","key":"2026020612013801500_bib100","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2026020612013801500_bib101","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat Commun"},{"key":"2026020612013801500_bib102","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.02.636108","article-title":"RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance","author":"Kennedy","year":"7  2025","journal-title":"bioRxiv"},{"issue":"21","key":"2026020612013801500_bib103","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026020612013801500_bib104","first-page":"1766","article-title":"Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax\/azacitidine","volume":"109","author":"Winters","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2026020612013801500_bib105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026020612013801500_bib106","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"2026020612013801500_bib107","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026020612013801500_bib108","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026020612013801500_bib109","doi-asserted-by":"crossref","first-page":"e93019","DOI":"10.7554\/eLife.93019","article-title":"Convergent epigenetic evolution drives relapse in acute myeloid leukemia","volume":"13","author":"Nuno","year":"2024","journal-title":"eLife"},{"issue":"4","key":"2026020612013801500_bib110","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.xpro.2023.102641","article-title":"A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells","volume":"4","author":"Turkalj","year":"2023","journal-title":"STAR Protoc"},{"issue":"8014","key":"2026020612013801500_bib111","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41586-024-07388-y","article-title":"Mapping genotypes to chromatin accessibility profiles in single cells","volume":"629","author":"Izzo","year":"2024","journal-title":"Nature"},{"issue":"7661","key":"2026020612013801500_bib112","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"issue":"38","key":"2026020612013801500_bib113","doi-asserted-by":"crossref","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci Adv"},{"issue":"suppl 1","key":"2026020612013801500_bib114","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2024-210840","article-title":"Single-cell multi-omic analysis of AML MRD reveals differences in clonal architecture between relapse and non-relapse cases [abstract]","volume":"144","author":"Sciambi","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/6\/613\/2501621\/blood_bld-2024-027948-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/6\/613\/2501621\/blood_bld-2024-027948-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:01:55Z","timestamp":1770397315000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/6\/613\/548036\/Rapid-clonal-selection-within-early-hematopoietic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027948","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,5]]},"published":{"date-parts":[[2026,2,5]]}}}